SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending with retail traders actively discussing price targets and potential for a short squeeze. Despite recent earnings and raised guidance, some express concern over market conditions and volatility. Optimistic investors point to institutional ownership, AI momentum, and potential government reopening as catalysts for a rebound.

Peanut the Squirrel Markets

Peanut the Squirrel Markets ($PNUT) is surging, driven by community enthusiasm and speculative momentum reminiscent of other meme coins. Community members are actively discussing potential price targets and noting high trading volume, with some drawing comparisons to established meme coins and anticipating further gains. The coin's recent price action and increased visibility are fueling the current buzz.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending due to the recent acquisition of Sentrycs, a counter-UAS technology company, sparking discussions about its potential impact on revenue and market position. The community is weighing the significance of this move amidst a broader market downturn and government shutdown, with some highlighting the company's cash reserves and strategic positioning in the drone sector. There's also considerable debate around dilution risks and future growth prospects.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as investors flock to privacy coins, with community members discussing its potential to reach $1,000 and comparing it to Bitcoin's early days. A recent Coindesk article has added fuel to the fire, while some traders are pointing to a pullback. The coin's limited supply and focus on shielded transactions are key talking points.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics ($CAPR) is trending as investors eagerly await upcoming data from its Phase 3 HOPE-3 trial for Duchenne Muscular Dystrophy (DMD), with the community actively debating potential outcomes and FDA pathways. Discussions revolve around the trial's endpoints (PUL and LVEF), the possibility of accelerated approval, and the impact of recent FDA decisions on similar therapies. Some are also highlighting the potential of Capricor's StealthX exosome platform.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk Corp. is trending due to optimism around its potential in the inference market and high-bandwidth flash memory, with community members drawing comparisons to past high-growth tech stories. Despite some bearish sentiment focused on profitability, bullish traders are pointing to future earnings estimates and significant volume spikes as potential catalysts. The stock's parabolic year-to-date performance and analyst upgrades are fueling FOMO, while others caution about overvaluation and potential manipulation.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amid community discussions about potential rallies and long-term holding strategies, with some mentioning a recent ETF filing including SHIB. Despite mixed sentiment, some traders express optimism, while others remain skeptical about its future performance and potential for new all time highs. Community members highlight both bullish and bearish outlooks, and reference the broader meme coin sector.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as discussions revolve around the potential impact of the ongoing bidding war with Pfizer for Metsera, and speculation about an upcoming announcement from the Trump administration regarding drug pricing. Community sentiment is mixed, with some investors expressing frustration over the stock's recent performance, while others remain optimistic about the company's long-term prospects and potential catalysts like oral Wegovy approval and broader market access.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending as the community anticipates upcoming news and potential catalysts, particularly related to its pharmaceutical and battery technology ventures. Discussions revolve around the potential impact of the overfunded pension plan and the possibility of new partnerships or contracts. Some investors are drawing parallels to past meme stock rallies, while others highlight the company's undervalued status.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer's stock is active amid an ongoing bidding war with Novo Nordisk for Metsera, a company focused on obesity drugs, with Pfizer filing lawsuits to challenge Novo's acquisition. The community is discussing the implications of this battle, Pfizer's overall strategy in the weight loss market, and whether the company is overpaying for potential acquisitions. Additionally, the stock's dividend and recent earnings are focal points of conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner Kazia Therapeutics to Request...

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease...

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer Kazia Therapeutics announces the launch of a...

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering PR Newswire SYDNEY, Jan. 14, 2025...

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering Kazia Therapeutics Announces $2.0 Million Registered Direct Offering PR Newswire SYDNEY, Jan. 10, 2025 SYDNEY, Jan. 10, 2025...

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with...

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast...

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme Kazia Therapeutics Announces...

Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women

Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women PR Newswire...

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society f

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases...

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Limited - ADR

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

KZIA
Kazia Therapeutics

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest KZIA News

KZIAKazia Therapeutics